CN109336870A - Carbazoles STAT3 inhibitor crystal form I and preparation method thereof - Google Patents

Carbazoles STAT3 inhibitor crystal form I and preparation method thereof Download PDF

Info

Publication number
CN109336870A
CN109336870A CN201811283127.3A CN201811283127A CN109336870A CN 109336870 A CN109336870 A CN 109336870A CN 201811283127 A CN201811283127 A CN 201811283127A CN 109336870 A CN109336870 A CN 109336870A
Authority
CN
China
Prior art keywords
compound
formula
ethyl
methyl
carbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811283127.3A
Other languages
Chinese (zh)
Inventor
郭程杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd
Original Assignee
Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd filed Critical Nanjing Advanced Biomaterials And Process Equipment Research Institute Co Ltd
Priority to CN201811283127.3A priority Critical patent/CN109336870A/en
Publication of CN109336870A publication Critical patent/CN109336870A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The invention belongs to medicinal chemistry arts, more particularly to compound 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1 with function of tumor, 3, a kind of novel crystal forms, preparation method, the composition comprising the crystal form of 5- triazine -2- amine maleate, and the purposes of the crystal form or the composition comprising the crystal form in medicine preparation, the I crystal has good physical and chemical stability, solubility and bioavilability, is suitble to formulation development.

Description

Carbazoles STAT3 inhibitor crystal form I and preparation method thereof
Technical field
The invention belongs to medicinal chemistry arts, and in particular to the compound 4- (9- ethyl -9H- carbazole-with function of tumor 4- yl) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate A kind of novel crystal forms, preparation method, the composition comprising the crystal form and the crystal form or the combination comprising the crystal form Purposes of the object in medicine preparation.
Background technique
Cancer is the general designation of a major class malignant tumour, its main feature is that without limitation, without end hyperplasia.Cancer cell makes patient's body Interior nutriment is largely consumed, while releasing a variety of toxin, and human body is made to generate a series of symptoms, cause human body it is thin, Inability, anaemia, loss of appetite, fever and serious organ function are impaired, cause necrotic hemorrhage concurrent infection, patient finally by It is dead in organ failure.
Signal transduction and (the Signal Transducer and Activator of of activating transcription factor -3 Transcription-3, STAT3) be a kind of GAP-associated protein GAP that can be activated by different cytokine receptors, cell because Carrier is served as during son-acceptor interaction, the inherence specificity for keeping signal to transmit in the cell, and pass through induction target The effect effect of biostimulation is expressed in genetic transcription, other than participating in angiogenesis and immune response, also with the increasing of cell It grows, survive, breaking up, the close associations such as anti-apoptotic.STAT3 is in kinds of tumor cells (including blood such as leukaemia, Huppert's disease A variety of entity tumors such as liquid tumour and lung cancer, breast cancer, prostate cancer) in abnormal expression increase, generation with malignant tumour, Develop closely related.
By inhibiting STAT3 activity to be expected to that cancer cell is made apoptosis occur to achieve the purpose that treating cancer, study recently It was found that inhibiting STAT3 signal that can overcome the chemical drug resistance including kinds of tumors such as retinoblastoma, lung cancer, leukaemia Property, successfully research and development are a new antitumor target to STAT3.Therefore, new STAT3 inhibitor is actively found for cancer Treatment have particularly important meaning.
Compound 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene - 4- ketone group) -1,3,5-triazines -2- amine maleate, there is formula:
The Compound ira vitro cytoactive detection finds that it has good inhibitory activity to prostate gland cancer cell DU-145, IC50Value is 9.0nM, also has good inhibitory activity, IC to human breast cancer cell MDA-MB-46850Value is 19.7nM, is had Good application prospect.
This field knows that the difference of drug crystal forms will cause the difference of various physicochemical properties, as solubility, dissolution rate, Fusing point, density, hardness, optical and electrical properties, steam pressure etc..These differences can be reflected in thermodynamic stability, as stable type, Metastable type and instability mode；It can also be reflected on physical and chemical stability, such as hygroscopicity, crystal transfer, sample degradation.This A little differences directly affect prescription preparation process, storage method, internal medicine the generation dynamic performance of drug, and then influence the safety of drug Property and validity.
Therefore, 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color is studied Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate polymorphism and select significant and steady on clinical treatment Fixed controllable crystal form tool is of great significance to.
Summary of the invention
To 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- Ketone group) -1,3,5-triazines -2- amine maleate crystal form research in, the present inventor has found tens kinds of crystal forms altogether, real It tests and shows in obtained numerous crystal forms, wherein I crystal has good physical and chemical stability, solubility and biological utilisation Degree is suitble to formulation development.
It is an object of the present invention to provide compound 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl acylamino-s Phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate a kind of crystalline substance for being named as I crystal Type, the crystal form have good physical and chemical stability, solubility and bioavilability.
It is a further object to provide the preparation methods of the I crystal, and this method is easy to operate, convenient for industrialization Mass production.
It is also another object of the present invention to provide the medicines for containing the I crystal and at least one pharmaceutically acceptable carrier Use composition.
Fourth object of the present invention is to provide a kind of I crystal in preparation prevention and/or the drug for the treatment of tumour In application.
For foregoing invention purpose, in a first aspect, the present invention provides 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl Amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal, use Cu- Ka radiation, X-ray powder diffraction 2 θ of the angle of diffraction be 7.9 ± 0.2 °, 9.3 ± 0.2 °, 14.8 ± 0.2 °, 16.3 ± 0.2 °, Characteristic peak is shown at 25.5 ± 0.2 °.
This field knows, when with the crystallization of X-ray diffraction measure compound, due to the instrument of measurement or condition of measurement etc. Influence, for measured summit, there are the relative intensities of certain measurement error, especially x-ray diffraction pattern with test The variation of condition and change.For example, the evaluated error of 2 θ values can be about ± 0.2 °, the evaluated error of relative intensity can for ± 20%.Therefore, when determining every kind of crystalline texture, it should take into account this error.It can be understood as any and the application I There is crystal form the crystal form of essentially identical or similar x-ray diffraction pattern to belong within scope of the present application.
Specifically, 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- provided by the invention Methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal, it is radiated using Cu-Ka, X-ray powder Diffraction 2 θ of the angle of diffraction be 6.9 ± 0.2 °, 7.9 ± 0.2 °, 9.3 ± 0.2 °, 13.6 ± 0.2 °, 14.8 ± 0.2 °, 16.3 ± 0.2°、18.4±0.2°、21.5±0.2°、23.0±0.2°、24.3±0.2°、25.5±0.2°、28.9±0.2°、32.2± Characteristic peak is shown at 0.2 °.
More specifically, 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-provided by the invention N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal, is radiated, X-ray using Cu-Ka Powder diffraction 2 θ of the angle of diffraction be 6.0 ± 0.2 °, 6.9 ± 0.2 °, 7.9 ± 0.2 °, 9.3 ± 0.2 °, 13.6 ± 0.2 °, 14.8 ± 0.2°、16.3±0.2°、18.4±0.2°、21.5±0.2°、23.0±0.2°、24.3±0.2°、25.5±0.2°、28.9± Characteristic peak is shown at 0.2 °, 32.2 ± 0.2 °, 34.4 ± 0.2 °.
4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl-provided by the invention 4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal have X- diffraction pattern as described in Figure 1.
Second aspect, the present invention provide 4- of the invention (9- ethyl -9H- carbazole -4- base) -6- (4- acrylyl aminobenzene Base)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal preparation method, the side Method includes the following steps:
The compound of formula (1) is made in step a:2- hydroxy acetophenone acetylation；
Step b: the compound of formula (2) is made in the compound cyclization of formula (1)；
Step c: the compound of formula (3) is made in the compound bromo of formula (2)；
Step d: the compound amino of formula (3) replaces the compound that formula (4) are made；
The compound of formula (5) is made in step e:4- nitrobenzene methyl and biuret cyclization；
Step f: the compound of formula (6) is made in the compound chloro of formula (5)；
Step g: the compound of formula (6) reacts the compound that formula (7) are made with the compound of formula (4)；
Step h: the compound and 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- ethyl-of formula (7) The compound of formula (8) is made in 9H- carbazole reaction；
Step i: the compound reduction of formula (8) hydrogenates the compound that formula (9) are made；
Step j: the compound of formula (9) reacts the compound that formula (I) is made with acryloyl chloride；
Step k: the compound of formula (I) is reacted with maleic acid is made formula (I) compound maleate, by gained maleate Isopropanol-ethyl acetate in the mixed solvent is added, reflux, 0-5 DEG C of crystallization is to get 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal, instead Answer route as follows:
According to the preparation method, the solvent that formula (I) compound is reacted with maleic acid in step k is selected from alcohol, ketone, acetic acid second Ester or their mixture；Preferably, the solvent that formula (I) compound is reacted with maleic acid is selected from methanol, ethyl alcohol, acetone, acetic acid Ethyl ester or their mixture；It is further preferred that the solvent that formula (I) compound is reacted with maleic acid is methanol or ethyl alcohol.
According to the preparation method, the molar ratio that formula (I) compound is reacted with maleic acid in step k is about 1:0.5- 0.55；Preferably, the molar ratio that formula (I) compound is reacted with maleic acid is about 1:0.5.
According to the preparation method, isopropanol described in step k-ethyl acetate in the mixed solvent isopropanol and acetic acid second The volume ratio of ester is 10~15:1；Preferably, isopropanol described in step k-ethyl acetate in the mixed solvent isopropanol and second The volume ratio of acetoacetic ester is 10:1.
According to the preparation method, isopropanol described in step F-ethyl acetate mixed solvent usage amount is every gram of 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- three Piperazine -2- amine maleate uses isopropanol-ethyl acetate mixed solvent 15-25mL；Preferably, isopropanol-described in step F The usage amount of ethyl acetate mixed solvent is every gram of 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleic acid uses isopropanol-ethyl acetate mixed solvent 20mL.
The third aspect, the present invention provide pharmaceutical composition, and it includes 4- of the invention (9- ethyl -9H- carbazole -4- base) - 6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal and Pharmaceutically acceptable carrier.By 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl - 4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal and pharmaceutically acceptable carrier be mixed with patent medicine Object preparation, to be suitable for oral or parenteral.Medication includes, but are not limited in intradermal, intramuscular, peritonaeum, is intravenous, Subcutaneously, intranasally and peroral route.The preparation can be applied by any approach, such as by being transfused or injecting, by through upper The approach application that skin or mucocutaneous (such as oral mucosa or rectum etc.) absorb.Administration can be whole body or local.Through The example of mouth application preparation includes solid or liquid dosage form, specifically, including tablet, pill, granula, pulvis, capsule, sugar Slurry, emulsion, suspension etc..The preparation can be prepared by methods known in the art, and include that field of pharmaceutical preparations routinely makes Carrier.
Fourth aspect, the present invention provide 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- Methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal or 4- (9- ethyl -9H- carbazole -4- base) -6- The medicine of (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal Application of the compositions in the drug of preparation prevention and/or treatment tumour, including easily crowd is sent out to tumour or tumor patient is applied With 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl-of the invention of therapeutically effective amount 4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal or 4- (9- ethyl -9H- carbazole -4- base) -6- (4- alkene Propionamido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal medicine group Object is closed, Tumor incidence is effectively reduced, extends tumor patient life, the tumour includes but is not limited to prostate cancer, cream Gland cancer.
4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color of the invention Alkene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal is with good stability, solubility and bioavilability, it fits It shares in pharmaceutical preparation is made.
Detailed description of the invention
Fig. 1 is 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene - 4- ketone group) -1,3,5- triazine -2- amine maleate I crystal x-ray diffraction pattern.
Specific embodiment
The present invention is explained in more detail with reference to embodiments, the embodiment of the present invention is merely to illustrate technology of the invention Scheme not limits the scope of the invention.
The preparation of 1 2- aminomethyl -4H- chromene -4- keto hydrochloride of embodiment
The preparation of step 1 2- acetoxy acetophenone
2- hydroxy acetophenone (100mmol), chloroacetic chloride (250mmol) and potassium carbonate (500mmol) are added in reaction flask, 300ml acetone is added, back flow reaction 12h, after reaction, water, ethyl acetate extraction, anhydrous sulphur is added in evaporating solvent under reduced pressure Sour sodium is dry, is concentrated to give grease, directly throws in next step.
The preparation of step 2 2- methyl -4H- chromene -4- ketone
2- acetoxy acetophenone (50mmol) is weighed in reaction flask, 100ml DMSO is added and dissolves, at 0-5 DEG C in batches It is added sodium hydrogen (150mmol), finishes, be warmed to room temperature stirring 3h and water, dilute hydrochloric acid tune pH are added into reaction solution after reaction It is worth faintly acid, ethyl acetate extraction, anhydrous sodium sulfate is dry, is concentrated to give grease, and 100ml second is added into gained grease Acid and 5 drop concentrated hydrochloric acids, back flow reaction about 3h, reaction terminate, reaction solution are spin-dried for, and water, ethyl acetate extraction, anhydrous slufuric acid is added Sodium is dry, and column chromatographic purifying obtains title compound.
ES:M/Z 161 [M+H]+。
The preparation of step 3 2- bromomethyl -4H- chromene -4- ketone
By step 2 gained 2- methyl -4H- chromene -4- ketone (10mmol), N-bromosuccinimide (NBS, 10mmol) and Benzoyl peroxide (BPO, 0.95mmol) is added in reaction flask, and 20ml carbon tetrachloride is added to dissolve, back flow reaction 12h, reaction knot Shu Hou, reaction solution add water, and ethyl acetate extraction, anhydrous sodium sulfate is dry, and column chromatographic purifying obtains title compound.
ES:M/Z 239 [M+H]+。
The preparation of step 4 2- aminomethyl -4H- chromene -4- keto hydrochloride
Step 3 gained 2- bromomethyl -4H- chromene -4- ketone (0.5mmol) is added in reaction flask, it is molten that 5ml DMF is added Solution is added 2ml ammonium hydroxide, 12h is stirred at room temperature, and after reaction, water, ethyl acetate extraction is added in reaction solution, and anhydrous sodium sulfate is done Dry, filtering is spin-dried for, and ethyl acetate 5ml is added, and the ethyl acetate hydrogen chloride solution of saturation is added after stirring and dissolving to supernatant layer nothing Precipitating generates, and filters, dry, obtains title compound.
ES:M/Z 239 [M+H]+。
The preparation of chloro- 6- (4- the nitrobenzophenone) -1,3,5- triazine of 2 2,4- of embodiment bis-
The preparation of step 1 4- nitrobenzene methyl
4- nitrobenzoic acid (250mmol) is weighed in reaction flask, the dissolution of 300mL methanol is added, thionyl chloride is added dropwise (375mmol) drips and finishes back flow reaction 12h, and after reaction, decompression is spin-dried for, and saturated sodium bicarbonate solution is added and adjusts pH to 7- 8, ethyl acetate extraction, anhydrous sodium sulfate is dry, is concentrated to give title compound, directly throws in next step.
The preparation of step 2 6- (4- nitrobenzophenone) -1,3,5- triazine -2,4- (1H, 3H)-diketone
Biuret (100mmol) is weighed in reaction flask, the dissolution of 150mL glycol dimethyl ether is added, adds in batches at 0-5 DEG C Enter sodium hydride (83.4mmol), finish, be stirred to react 1h at 50 DEG C, adds 4- nitrobenzene methyl (83.4mmol), add Finish, be warming up to 85 DEG C of reaction 20h and be after reaction poured into water reaction solution, adjusts pH to acidity with concentrated hydrochloric acid, filter, filter Cake drying, obtains title compound.
ES:M/Z 235 [M+H]+。
The preparation of step 3 2,4- bis- chloro- 6- (4- nitrobenzophenone) -1,3,5- triazine
6- (4- nitrobenzophenone) -1,3,5-triazines -2,4- (1H, 3H)-diketone (200mmol) is added in reaction flask, is added Entering 200mL phosphorus oxychloride, phosphorus pentachloride (800mmol), reaction solution is poured into water by 105 DEG C of reaction 12h after reaction, and two Chloromethanes extraction, anhydrous sodium sulfate is dry, is concentrated to give title compound.
ES:M/Z 275 [M+H]+。
The chloro- 6- of 3 4- of embodiment (4- nitrobenzophenone)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine Preparation
Chloro- 6- (4- the nitrobenzophenone) -1,3,5- triazine (50mmol) of 2 gains 2,4- of embodiment bis- is weighed in reaction flask In, the dissolution of 100mL tetrahydrofuran is added, 1 gains 2- aminomethyl -4H- chromene -4- keto hydrochloride 2- (trifluoro of embodiment is added Methyl)-pyridine -4- amine (55mmol), sodium carbonate (100mmol), back flow reaction 72h, filtering, column chromatographic purifying obtains title compound Object.
ES:M/Z 416 [M+H]+。
The preparation of 4 4- of embodiment (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- ethyl -9H- carbazole The preparation of the chloro- 9- ethyl -9H- carbazole of step 1 4-
4- chlorine carbazole (5.46mmol) is weighed in reaction flask, 20mL THF dissolution is added, is cooled to -10 DEG C, NaH is added (14mmol), finishes, and after stirring 30 minutes, adds bromoethane (6mmol), finishes, reacts at room temperature 3h, and reaction terminates, and water quenching is added to go out, Ethyl acetate extraction, dry, concentration is prepared chromatogram purification and obtains the chloro- 9- ethyl -9H- carbazole of 4-.
ES:M/Z 230 [M+H]+。
The preparation of step 2 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- ethyl -9H- carbazole
Weigh the chloro- 9- ethyl -9H- carbazole (1mmol) of step 1 gains 4-, connection pinacol borate (1.1mmol), vinegar Sour potassium (2mmol) and 1,1'- bis(diphenylphosphino) ferrocene dichloropalladium (Pd (dppf) Cl2, 2mmol) and in reaction flask, add Entering 5mL Isosorbide-5-Nitrae-dioxane, for 24 hours, after reaction, water is added in 100 DEG C of reactions under the conditions of nitrogen protection, and ethyl acetate extracts, Merge organic phase, saturated common salt water washing merges organic phase, dries, filters, and is concentrated, and column chromatographic purifying obtains title compound.
5 4- of embodiment (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine preparation
Step 1 4- (9- ethyl -9H- carbazole -4- base) -6- (4- nitrobenzophenone)-N- (2- methyl -4H- chromene -4- ketone Base) -1,3,5- triazine -2- amine preparation
In 30ml microwave reaction bottle, embodiment 3 gained mixture 4- chloro- 6- (4- nitrobenzophenone)-N- (2- is sequentially added Methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine (10mmol), 4 gains 4- (4,4,5,5- tetramethyl-of embodiment 1,3,2- dioxolane borine) -9- ethyl -9H- carbazole (10mmol), [bis- (diphenylphosphine) ferrocene of 1,1'-] dichloride Palladium dichloromethane complex (0.1mmol), x-phos (0.4mmol), cesium carbonate (100mmol) and 1,4- dioxane/H2O (60ml/10ml), dissolution, argon gas displacement, 105 DEG C of microwave reaction 90min, concentration, column chromatographic purifying obtain title compound.
ES:M/Z 575 [M+H]+。
Step 2 4- (9- ethyl -9H- carbazole -4- base) -6- (4- aminophenyl)-N- (2- methyl -4H- chromene -4- ketone Base) -1,3,5- triazine -2- amine preparation
Weigh step 1 gains 4- (9- ethyl -9H- carbazole -4- base) -6- (4- nitrobenzophenone)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine (1mmol), 10%Pd-C (10mg) in reaction flask, be added 15ml methanol, at 1 Normal atmosphere pressure, H21h is restored, reaction is stopped, title compound is concentrated in filtering, is directly used in next step.
ES:M/Z 545 [M+H]+。
Step 3 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene - 4- ketone group) -1,3,5- triazine -2- amine preparation
Weigh step 2 gains 4- (9- ethyl -9H- carbazole -4- base) -6- (4- aminophenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine (0.1mmol), diisopropylethylamine (0.3mmol) in reaction flask, be added 15ml Anhydrous methylene chloride dissolution, is slowly dropped into methylene chloride (1ml) solution dissolved with allyl acyl chlorides (0.12mmol), 10min Fully reacting, concentration, column chromatographic purifying obtain title compound.
1H NMR(600MHz,CDCl3) (δ, ppm): 10.12 (s, 1H), 8.12 (m, 1H), 7.80~7.82 (m, 2H), 7.78~7.79 (m, 1H), 7.67~7.69 (m, 2H), 7.50~7.52 (m, 2H), 7.43~7.45 (m, 2H), 7.31~ 7.32 (m, 2H), 7.07~7.09 (m, 2H), 6.97~6.99 (m, 1H), 6.68~6.70 (m, 1H), 6.02~6.04 (m, 1H), 5.56 (s, 1H), 5.50~5.52 (m, 1H), 4.88 (s, 1H), 4.46~4.51 (m, 3H), 3.06~3.08 (m, 2H), 2.81~2.84 (m, 2H), 2.01~2.03 (brs, 2H), 1.91~1.93 (brs, 1H), 1.30~1.31 (t, 3H)
ES:M/Z 599 [M+H]+。
Embodiment 6:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate preparation
5 compound of embodiment (1mmol) is weighed in reaction flask, adds methanol 20mL, at room temperature after stirring and dissolving, horse is added Come sour (0.5mmol), finish, flow back 0.5h, is cooled to room temperature, evaporating solvent under reduced pressure, and vacuum drying obtains titled at room temperature Close object.
Embodiment 7:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate preparation
5 compound of embodiment (1mmol) is weighed in reaction flask, adds acetone 20mL, at room temperature after stirring and dissolving, horse is added Come sour (0.55mmol), finish, flow back 0.5h, is cooled to room temperature, evaporating solvent under reduced pressure, and vacuum drying obtains titled at room temperature Close object.
Embodiment 8:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate preparation
5 compound of embodiment (1mmol) is weighed in reaction flask, adds ethyl alcohol 20mL, at room temperature after stirring and dissolving, horse is added Come sour (0.5mmol), finish, flow back 0.5h, is cooled to room temperature, evaporating solvent under reduced pressure, and vacuum drying obtains titled at room temperature Close object.
Embodiment 9:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal preparation
Weigh 1.0g4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine maleate in reaction flask, be added 20mL volume ratio be 10:1 isopropanol-second Acetoacetic ester mixed solution, flow back 30min, cooled to room temperature, and 0-5 DEG C of crystallization is stayed overnight, and obtains 4- (9- ethyl -9H- carbazole - 4- yl) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I Crystal form.
Embodiment 10:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal preparation
Weigh 1.0g4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine maleate in reaction flask, be added 25mL volume ratio be 10:1 isopropanol-second Acetoacetic ester mixed solution, flow back 30min, cooled to room temperature, and 0-5 DEG C of crystallization is stayed overnight, and obtains 4- (9- ethyl -9H- carbazole - 4- yl) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I Crystal form.
Embodiment 11:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal preparation
Weigh 1.0g4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine maleate in reaction flask, be added 15mL volume ratio be 15:1 isopropanol-second Acetoacetic ester mixed solution, flow back 30min, cooled to room temperature, and 0-5 DEG C of crystallization is stayed overnight, and obtains 4- (9- ethyl -9H- carbazole - 4- yl) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I Crystal form.
4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- of above embodiments 9-11 preparation (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal through measurement there is essentially identical X to penetrate Ray diffraction diagram spectrum, is shown in Fig. 1.
Embodiment 12: biological activity determination
Compound prepares: the compound that the full-automatic microwell plate pretreatment system of POD810 is prepared the embodiment of the present invention 6 It is added in orifice plate, compound initial concentration is 100uM, and each compound does duplicate hole, 2 times of dilutions, 10 points.
The culture of cell: prostate gland cancer cell DU-145, human breast cancer cell MDA-MB-468 are used contain 15% tire respectively The RPMI-1640 culture medium of cow's serum (FBS) is cultivated in 37 degree of incubators, and logarithmic growth phase cell is for testing.
The experiment of MTT cells viability: prostate gland cancer cell DU-145, human breast cancer cell MDA-MB-468 are inoculated with respectively In 96 orifice plates (5-10 × 104cells/well), handle 48h with the compound of embodiment 6, be added in every hole 20 μ l 3- (4, 5- dimethylthiazole -2) -2,5- diphenyltetrazolium bromide bromide (MTT) hatching 4h, 100 μ l DMSO in every hole is then added, sets and shakes Low-speed oscillation 10min on bed, dissolves crystal sufficiently.The extinction in each hole is measured at enzyme-linked immunosorbent assay instrument OD 490nm Value, handles to obtain homologous thread and IC using GraphPad Prism50Value, the results are shown in Table 1.
Table 1
The experimental results showed that 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl - 4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate is to the active MDA-MB-468 of STAT3 with sustained activation Cell, DU-145 cell have good inhibiting effect.
Embodiment 13: water solubility evaluation
By pharmacopeia four water-soluble experiments in 2015, experimental result was shown in Table 2.
Table 2
Compound It is water-soluble
9 compound of embodiment 35.81mg/ml
Embodiment 14:4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal stability test
Weigh 3 parts of 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal 0.5g, it is laid in culture dish respectively, 1 part of opening is placed in light It is placed under the conditions of being 4500Lx ± 500Lx according to illumination 30 days, 1 part of opening is placed under the conditions of being placed in 85% relative humidity of room temperature (RH) 30 days, 1 part of opening was placed 30 days under the conditions of being placed in 95% relative humidity of room temperature (RH), is sampled in the 0th, 10,30 day, and examination is maximum Single miscellaneous, total impurities, crystal form and appearance variations, experimental result are shown in Table 3.
Table 3
Above-mentioned experimental result shows 4- of the invention (9- ethyl -9H- carbazole -4- base) -6- (4- acrylyl aminobenzene Base)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal have good chemical stabilization Property and physical stability.

Claims (10)

1.4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) - The I crystal of 1,3,5-triazines -2- amine maleate, is radiated using Cu-Ka, and X-ray powder diffraction is 7.9 in 2 θ of the angle of diffraction Characteristic peak is shown at ± 0.2 °, 9.3 ± 0.2 °, 14.8 ± 0.2 °, 16.3 ± 0.2 °, 25.5 ± 0.2 °.
2. I crystal as described in claim 1, it is characterised in that: radiated using Cu-Ka, X-ray powder diffraction is in diffraction 2 θ of angle be 6.9 ± 0.2 °, 7.9 ± 0.2 °, 9.3 ± 0.2 °, 13.6 ± 0.2 °, 14.8 ± 0.2 °, 16.3 ± 0.2 °, 18.4 ± It is shown at 0.2 °, 21.5 ± 0.2 °, 23.0 ± 0.2 °, 24.3 ± 0.2 °, 25.5 ± 0.2 °, 28.9 ± 0.2 °, 32.2 ± 0.2 ° Characteristic peak.
3. I crystal as described in claim 1, it is characterised in that: radiated using Cu-Ka, X-ray powder diffraction is in diffraction 2 θ of angle be 6.0 ± 0.2 °, 6.9 ± 0.2 °, 7.9 ± 0.2 °, 9.3 ± 0.2 °, 13.6 ± 0.2 °, 14.8 ± 0.2 °, 16.3 ± 0.2°、18.4±0.2°、21.5±0.2°、23.0±0.2°、24.3±0.2°、25.5±0.2°、28.9±0.2°、32.2± Characteristic peak is shown at 0.2 °, 34.4 ± 0.2 °.
4. the preparation method of the described in any item I crystals of claim 1-3, includes the following steps:
The compound of formula (1) is made in step a:2- hydroxy acetophenone acetylation；
Step b: the compound of formula (2) is made in the compound cyclization of formula (1)；
Step c: the compound of formula (3) is made in the compound bromo of formula (2)；
Step d: the compound amino of formula (3) replaces the compound that formula (4) are made；
The compound of formula (5) is made in step e:4- nitrobenzene methyl and biuret cyclization；
Step f: the compound of formula (6) is made in the compound chloro of formula (5)；
Step g: the compound of formula (6) reacts the compound that formula (7) are made with the compound of formula (4)；
Step h: the compound and 4- (4,4,5,5- tetramethyl -1,3,2- dioxolane borine) -9- ethyl -9H- click of formula (7) Azoles reacts the compound that formula (8) are made；
Step i: the compound reduction of formula (8) hydrogenates the compound that formula (9) are made；
Step j: the compound of formula (9) reacts the compound that formula (I) is made with acryloyl chloride；
Step k: the compound of formula (I) is reacted with maleic acid is made formula (I) compound maleate, and gained maleate is added Isopropanol-ethyl acetate in the mixed solvent, reflux, 0-5 DEG C of crystallization is to get 4- (9- ethyl -9H- carbazole -4- base) -6- (4- alkene Propionamido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5-triazines -2- amine maleate I crystal, reaction route It is as follows:
5. preparation method as claimed in claim 4, it is characterised in that: formula (I) compound reacts molten with maleic acid in step k Agent is selected from alcohol, ketone, ethyl acetate or their mixture；Preferably, the solvent that formula (I) compound is reacted with maleic acid is selected from first Alcohol, ethyl alcohol, acetone, ethyl acetate or their mixture；It is further preferred that formula (I) compound reacts molten with maleic acid Agent is methanol or ethyl alcohol.
6. preparation method as claimed in claim 4, it is characterised in that: what formula (I) compound was reacted with maleic acid in step k rubs Your ratio is about 1:0.5-0.55；Preferably, the molar ratio that formula (I) compound is reacted with maleic acid is about 1:0.5.
7. preparation method as claimed in claim 4, it is characterised in that: isopropanol described in step k-ethyl acetate mixing is molten The volume ratio of isopropanol and ethyl acetate is 10~15:1 in agent；Preferably, isopropanol-ethyl acetate described in step k is mixed The volume ratio of isopropanol and ethyl acetate is 10:1 in bonding solvent.
8. preparation method as claimed in claim 4, it is characterised in that: isopropanol described in step F-ethyl acetate mixing is molten The usage amount of agent is every gram of 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- color Alkene -4- ketone group) -1,3,5- triazine -2- amine maleate use isopropanol-ethyl acetate mixed solvent 15-25mL；Preferably, Isopropanol described in step F-ethyl acetate mixed solvent usage amount is every gram of 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleic acid uses isopropanol - Ethyl acetate mixed solvent 20mL.
9. a kind of pharmaceutical composition includes the described in any item 4- of claim 1-3 (9- ethyl -9H- carbazole -4- base) -6- (4- Allyl amido phenyl)-N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal and pharmacy Upper acceptable carrier.
10. claim 1-3 described in any item 4- (9- ethyl -9H- carbazole -4- base) -6- (4- allyl amido phenyl) - N- (2- methyl -4H- chromene -4- ketone group) -1,3,5- triazine -2- amine maleate I crystal or medicine group as claimed in claim 9 Close application of the object in the drug of preparation prevention and/or treatment tumour.
CN201811283127.3A 2018-10-31 2018-10-31 Carbazoles STAT3 inhibitor crystal form I and preparation method thereof Withdrawn CN109336870A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811283127.3A CN109336870A (en) 2018-10-31 2018-10-31 Carbazoles STAT3 inhibitor crystal form I and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811283127.3A CN109336870A (en) 2018-10-31 2018-10-31 Carbazoles STAT3 inhibitor crystal form I and preparation method thereof

Publications (1)

Publication Number Publication Date
CN109336870A true CN109336870A (en) 2019-02-15

Family

ID=65313041

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811283127.3A Withdrawn CN109336870A (en) 2018-10-31 2018-10-31 Carbazoles STAT3 inhibitor crystal form I and preparation method thereof

Country Status (1)

Country Link
CN (1) CN109336870A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578663A (en) * 2001-09-14 2005-02-09 梅特希尔基因公司 Inhibitors of histone deacetylase
US20140045908A1 (en) * 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1578663A (en) * 2001-09-14 2005-02-09 梅特希尔基因公司 Inhibitors of histone deacetylase
US20140045908A1 (en) * 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. STEPHEN K. HASHMI， 等: "Gold(I)-Catalyzed Rearrangement of 3-Silyloxy-1,5-enynes: An Efficient Synthesis of Benzo[b]thiophenes, Dibenzothiophenes, Dibenzofurans, and Indole Derivatives" *
CARMEN ESCOLANO，等: "Aryl radical cyclisation onto pyrroles" *

Similar Documents

Publication Publication Date Title
BR112018008877B1 (en) RET-INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES OF SUCH COMPOUNDS
UA123010C2 (en) Cot modulators and methods of use thereof
CN107118207A (en) The preparation method of one class CDK inhibitor
CN107056755A (en) Five-ring heterocycles amide-type WNT pathway inhibitors
CN108947974A (en) A kind of amino-metadiazine compound and the composition comprising the compound and application thereof
CN109336870A (en) Carbazoles STAT3 inhibitor crystal form I and preparation method thereof
CN109336867A (en) Carbazoles STAT3 inhibitor crystal form A and preparation method thereof
CN109966297A (en) A kind of taxol and carbazoles STAT inhibitor maleate crystal form I drug combination compositions
CN109369628A (en) Carbazoles STAT3 inhibitor crystal form II and preparation method thereof
CN109288845A (en) A kind of carbazoles STAT inhibitor maleate crystal form II drug combination compositions and preparation method thereof
CN109288846A (en) A kind of taxol and carbazoles STAT3 inhibitor crystal form A drug combination compositions
CN109369626A (en) Carbazoles STAT3 inhibitor P crystal form and preparation method thereof
CN107235931B (en) New pyrimidine anti-tumor compounds and preparation method thereof and purposes
CN109288847A (en) A kind of taxol and carbazoles STAT inhibitor Mesylate Form P drug combination compositions
CN109293647A (en) The M crystal form and preparation method thereof of dibenzo [b, d] thiophene-based STAT3 inhibitor
KR20100032496A (en) Novel 5-(4-aminophenyl)-isoquinoline derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by overactivation of raf kinase containing the same as an active ingredient
CN109180657A (en) The preparation method of STAT3 inhibitor
CN108947961B (en) Indazole derivative and preparation method and application thereof
CN109331004A (en) A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor mesylate A crystal form drug combination compositions
CN109200044A (en) A kind of taxol and dibenzo [b, d] thiophene-based STAT inhibitor tartrate drug combination compositions
JP2019535751A (en) COMPOUND HAVING ANTI-CANCER ACTIVITY, PROCESS FOR PRODUCING THE SAME AND USE THEREOF
CN109336876A (en) Tartrate of dibenzo [b, d] thiophene-based STAT3 inhibitor and preparation method thereof and purposes
CN109336877A (en) Mesylate of dibenzo [b, d] thiophene-based STAT3 inhibitor and preparation method thereof and purposes
TW202222315A (en) Salts of FXIa inhibitor compounds, preparation method therefor, and pharmaceutical use thereof
CN109336871A (en) A kind of maleate of STAT3 inhibitor and preparation method thereof and purposes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190215